CDR Life Sciences Team supports Acacia Pharma’s €190 million Initial Global Offering
The CDR Life Sciences team supported Acacia Pharma on its successful €190 million Initial Global Offering (IGO) and listing on Euronext Brussels in March 2018. In raising EUR 40 million, Acacia Pharma’s listing is the largest on Euronext since 2015 and the first Pharma company listing on Euronext Brussels in 2018.
CDR continues to provide international strategic communications and IR consultancy to Acacia Pharma as the company moves into the next stage of development, most notably as it prepares for the US launch of its lead product BAREMSIS® for the treatment of post-operative nausea & vomiting (PONV), anticipated in 2019 pending approval in late 2018.
Acacia Pharma is a hospital pharmaceutical group focused on developing new nausea and vomiting treatments for surgical and chemotherapy patients. The company’s second candidate is APD403, which is in Phase II trials to treat chemotherapy induced nausea & vomiting (CINV) in cancer patients, a common and feared side effect of treatment.